ATE96035T1 - Verwendung eines polypeptides mit gammainterferon-aktivitaet zur herstellung von pharmazeutischen zusammensetzungen zur behandlung von primitivem pleura-krebs. - Google Patents

Verwendung eines polypeptides mit gammainterferon-aktivitaet zur herstellung von pharmazeutischen zusammensetzungen zur behandlung von primitivem pleura-krebs.

Info

Publication number
ATE96035T1
ATE96035T1 AT90403174T AT90403174T ATE96035T1 AT E96035 T1 ATE96035 T1 AT E96035T1 AT 90403174 T AT90403174 T AT 90403174T AT 90403174 T AT90403174 T AT 90403174T AT E96035 T1 ATE96035 T1 AT E96035T1
Authority
AT
Austria
Prior art keywords
polypeptide
preparation
treatment
primitive
pharmaceutical compositions
Prior art date
Application number
AT90403174T
Other languages
English (en)
Inventor
Maud Brandely
Danielle Lando
Original Assignee
Roussel Uclaf
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Roussel Uclaf filed Critical Roussel Uclaf
Application granted granted Critical
Publication of ATE96035T1 publication Critical patent/ATE96035T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/217—IFN-gamma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT90403174T 1989-11-10 1990-11-08 Verwendung eines polypeptides mit gammainterferon-aktivitaet zur herstellung von pharmazeutischen zusammensetzungen zur behandlung von primitivem pleura-krebs. ATE96035T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR898914780A FR2654343B1 (fr) 1989-11-10 1989-11-10 Utilisation d'un polypeptide ayant l'activite de l'interferon gamma pour la preparation de compositions pharmaceutiques destinees au traitement de cancers primitifs de la plevre.
EP90403174A EP0427633B1 (de) 1989-11-10 1990-11-08 Verwendung eines Polypeptides mit Gammainterferon-Aktivität zur Herstellung von pharmazeutischen Zusammensetzungen zur Behandlung von primitivem Pleura-Krebs

Publications (1)

Publication Number Publication Date
ATE96035T1 true ATE96035T1 (de) 1993-11-15

Family

ID=9387288

Family Applications (1)

Application Number Title Priority Date Filing Date
AT90403174T ATE96035T1 (de) 1989-11-10 1990-11-08 Verwendung eines polypeptides mit gammainterferon-aktivitaet zur herstellung von pharmazeutischen zusammensetzungen zur behandlung von primitivem pleura-krebs.

Country Status (14)

Country Link
US (1) US5108743A (de)
EP (1) EP0427633B1 (de)
JP (1) JPH07103042B2 (de)
KR (1) KR0169975B1 (de)
AT (1) ATE96035T1 (de)
AU (1) AU645042B2 (de)
CA (1) CA2029670A1 (de)
DE (1) DE69004051T2 (de)
DK (1) DK0427633T3 (de)
FR (1) FR2654343B1 (de)
HU (1) HU206049B (de)
IL (1) IL96229A (de)
OA (1) OA09469A (de)
ZA (1) ZA907649B (de)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2148988C1 (ru) * 1997-07-21 2000-05-20 Самойленко Игорь Иннокентьевич Усовершенствованная лекарственная форма человеческого интерферона-свеча
JP5043294B2 (ja) * 2003-09-29 2012-10-10 エー・デー・ガイストリヒ・ゾーネ・アクチェンゲゼルシャフト・フュール・ヒェーミシェ・インダストリー 中皮腫を治療する方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ217885A (en) * 1985-10-15 1989-06-28 Hoffmann La Roche Stabilised compositions of interferon
WO1987005518A1 (en) * 1986-03-17 1987-09-24 Schering Corporation Treatment of cancers with gamma interferon
ZA878295B (en) * 1986-11-06 1988-05-03 Amarillo Cell Culture Co. Inc. Treatment of immuno-resistant disease
EP0278715A3 (de) * 1987-02-09 1989-03-08 Schering Corporation Verwendung von menschlichem Gamma-Interferon für die Behandlung von Basalzell-Karzinomen

Also Published As

Publication number Publication date
AU645042B2 (en) 1994-01-06
KR0169975B1 (ko) 1999-02-01
DK0427633T3 (da) 1994-01-31
HU206049B (en) 1992-08-28
DE69004051T2 (de) 1994-03-03
EP0427633A1 (de) 1991-05-15
ZA907649B (en) 1991-11-27
IL96229A (en) 1998-04-05
IL96229A0 (en) 1991-08-16
EP0427633B1 (de) 1993-10-20
AU6651190A (en) 1991-05-16
US5108743A (en) 1992-04-28
HU907180D0 (en) 1991-05-28
JPH03188025A (ja) 1991-08-16
OA09469A (fr) 1992-11-15
JPH07103042B2 (ja) 1995-11-08
HUT55995A (en) 1991-07-29
FR2654343B1 (fr) 1994-08-05
DE69004051D1 (de) 1993-11-25
FR2654343A1 (fr) 1991-05-17
KR910009280A (ko) 1991-06-28
CA2029670A1 (fr) 1991-05-11

Similar Documents

Publication Publication Date Title
NZ227787A (en) Peptides and compositions having growth hormone regulatory effects
ATE79763T1 (de) Verwendung von mindestens ein cytokin zur herstellung eines arzneimittels zur systemischen behandlung von praeneoplastischen laesionen.
FI922151A0 (fi) Metall-peptidkompositioner och metoder foer stimulering av haortillvaext.
GR3007096T3 (de)
FR2483926B1 (de)
NL300106I1 (nl) N-terminaal chemisch gemodificeerde eiwitpreparaten en werkwijzen.
NZ266475A (en) Use of recombinant adenovirus of animal origin in making pharmaceutical composition
DE59101397D1 (de) O-glycosyliertes ifn-alpha.
ATE94387T1 (de) Verwendung von n-myristoyl-(s)-phenylalanin zur herstellung eines medikaments zur behandlung von krankheiten mittels hemmung der myristoylierung.
ATE54826T1 (de) Thymusextraktfraktionen enthaltende pharmazeutische zusammensetzung.
ATE84048T1 (de) Peptid, dessen verfahren zur herstellung, sie enthaltende pharmazeutische zusammensetzung und benutzung.
DE3777845D1 (de) Pharmazeutischer stoff fuer die behandlung von myelogener leukaemie.
DE68924006D1 (de) Pharmazeutische Zusammensetzungen mit Eierschalenbestandteilen und ihre Herstellung und Verwendung.
FI101597B1 (fi) Menetelmä kylmäkuivatun koostumuksen valmistamiseksi käytettäväksi potilaan valodynaamisessa hoidossa tai diagnosoinnissa
SG52537A1 (en) Methods and compositions for the treatment of cell proliferation disorders
DE69010294D1 (de) Verwendung von Antiprogestomimetika zur Stimulierung des Eisprungs.
DE69004794D1 (de) Verwendung eines Polypeptids mit Interleukin 2-Aktivität zur Herstellung einer zur Behandlung von einfachen Pleurageschwüren bestimmten pharmazeutischen Zusammensetzung.
ATE96035T1 (de) Verwendung eines polypeptides mit gammainterferon-aktivitaet zur herstellung von pharmazeutischen zusammensetzungen zur behandlung von primitivem pleura-krebs.
ZA81927B (en) Phenylpiperazine derivatives of 1,3,4-oxadiazolyphenols their preparation and therapeutic agents containing these compounds
ATE59780T1 (de) Pharmazeutische zusammensetzung zur behandlung von tumoren.
ATE45675T1 (de) Verwendung von interferon gamma (ifn-gamma) zur herstellung von praeparationen zur behandlung rheumatischer erkrankungen.
GR3005231T3 (de)
ATE107166T1 (de) Verwendung von chlormethiazol zur herstellung eines artzneimittels zur prophylaxe oder therapie der neurodegeneration.
DE69203098D1 (de) Verwendung eines Polypeptids mit humaner Interleukin-2 Aktivität zur Herstellung pharmazeutischer Zusammensetzungen zur Behandlung von Pneumothoraxen.
IT1238350B (it) Composizione per la profilassi anticarie dello smalto umano.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
EEIH Change in the person of patent owner
EELA Cancelled due to lapse of time